Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery (AddEase)

23 juli 2026 uppdaterad av: Montreal Heart Institute

Effectiveness of Adductor Canal Block in Postoperative Co-analgesia for Cardiac Surgery With Saphenous Vein Harvesting

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

120

Fas

  • Fas 2
  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Quebec
      • Montreal, Quebec, Kanada, H1T 1C8

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Planned CABG with unilateral or bilateral great saphenous vein (GSV) harvesting, without concomitant valve surgery
  • Age ≥ 18 years
  • Ability to understand the protocol and provide written informed consent
  • ASA physical status I-IV

Exclusion Criteria:

  • Refusal to participate in the study or inability to provide written informed consent
  • Contraindication to adductor canal block (e.g., local infection, allergy to local anesthetics)
  • Pre-existing chronic pain associated with chronic use of analgesic medications other than acetaminophen
  • Pre-existing peripheral neuropathy affecting the leg
  • Participation in two other interventional studies at the Montreal Heart Institute
  • Endoscopic vein harvesting performed by the surgical team instead of open saphenectomy technique

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Adductor canal bloc with bupivacaine + dexmedetomidine
Adductor canal bloc with 0,25% bupivacaine + 20 ucg of dexmedetomidine
Andra namn:
  • Pain relief arm
Placebo-jämförare: Control arm
Saline solution
Needle insertion mimicking the ACB procedure with injection of a saline solution

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Leg Pain at Rest
Tidsram: Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The primary outcome will be leg pain at rest, measured using a numeric rating scale (NRS 0-10) at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Total opioid consumption
Tidsram: The first 48 postoperative hours after procedure
Cumulative amount administered, expressed in morphine milligram equivalents (MME), during the first 48 postoperative hours (conversion factors used: hydromorphone 1 mg = morphine 5 mg; fentanyl 100 µg = morphine 10 mg).
The first 48 postoperative hours after procedure
Postoperative pain unrelated to the saphenous territory
Tidsram: Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Incidence and characterization of postoperative pain unrelated to the saphenous territory (e.g., thoracic or musculoskeletal pain), assessed at the same time points as saphenous pain using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.
Persistent Postoperative Pain
Tidsram: At 3 and 6 months postoperatively, assessed using the NRS.

Proportion of patients reporting pain ≥4/10 at the harvest site at 3 and 6 months postoperatively, assessed using the NRS.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively, assessed using the NRS.
Overall persistent postoperative pain
Tidsram: At 3 and 6 months postoperatively.

Proportion of patients reporting pain ≥4/10 (all sites combined) at 3 and 6 months postoperatively.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively.
Presence of hypoesthesia
Tidsram: Numeric rating scale at 3 and 6 months.

Presence of hypoesthesia (non-painful) at the saphenectomy site at 3 and 6 months using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale at 3 and 6 months.
Neuropathic characterization
Tidsram: At 48 hours, 3 months, and 6 months.

Quantification of the modified DN4 score at the harvest site at 48 hours, 3 months, and 6 months.

Modified DN4 ≥ 3/8: high probability of neuropathic pain Modified DN4 < 3/8: neuropathic pain unlikely

At 48 hours, 3 months, and 6 months.
Block safety
Tidsram: Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Number of adverse events related to the adductor canal block observed during the hospital stay, including hematoma, infection, nerve injury, cardiovascular complications, motor block, and signs of local anesthetic systemic toxicity.
Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Opioid-related side effects
Tidsram: Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Incidence of common opioid-related side effects in each group, including nausea, vomiting, and constipation.
Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Time to extubation
Tidsram: At extubation
Time to extubation after adductor canal block
At extubation

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Use of co-analgesia
Tidsram: Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Number of treatments used and frequency of use (lidocaine-ketamine cream, NSAIDs, gabapentinoids, etc.)
Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Postoperative quality of life
Tidsram: At 3 and 6 months postoperatively

EQ-5D score quantification measured at 3 and 6 months postoperatively. The EQ-5D (EuroQol - 5 Dimensions) is a standardized and validated instrument used to assess health-related quality of life across two components. It is widely used in clinical research to measure the overall impact of a medical intervention on patients' functional status and well-being.

It explores five dimensions of health:

  • Mobility
  • Self-care
  • Usual activities
  • Pain / discomfort
  • Anxiety / depression

Each dimension is assessed across 5 levels of severity:

  • No problems
  • Slight problems
  • Moderate problems
  • Severe problems
  • Extreme problems / inability

The combination of responses generates a 5-digit health profile, which can be converted into an EQ-5D index.

1.0: Represents perfect health. 0.0: Represents a state considered equivalent to death. Negative values: Health states deemed "worse than death."

At 3 and 6 months postoperatively
Opioid use
Tidsram: At 3 and 6 months postoperatively
Opioid use at 3 and 6 months postoperatively, assessed by the presence or absence of opioid use and the type of opioid used.
At 3 and 6 months postoperatively

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 augusti 2026

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

2 juni 2026

Först inskickad som uppfyllde QC-kriterierna

23 juli 2026

Första postat (Faktisk)

29 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data (IPD) will not be shared, as study documents are available only in French. However, upon reasonable request, the investigators will provide the study protocol, informed consent form, statistical analysis plan, and any other relevant documents.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera